



**EP PerMed**

European Partnership  
for **Personalised Medicine**

Research Innovation and Technology Call  
for Proposals (2026) for

**Test and Demonstration of Multimodal Data  
Approaches for Personalised Medicine  
("MultiPMDData2026")**

(EP PerMed Grant 101137129)

# Pre-announcement

**For further information, please visit our website:** [www.eppermed.eu](http://www.eppermed.eu)

**or contact the EP PerMed Joint Call Secretariat (JCS)**

The French National Research Agency (ANR)  
86 rue Regnault, 75013 Paris, FRANCE  
Mylène Vaillancourt, Mérick Machouri  
Phone: +33 1 78 09 80 36, +33 1 72 73 06 72  
EPPERMed@agencerecherche.fr



**Co-funded by  
the European Union**

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

## Preliminary Announcement for the first EP PerMed Research Innovation and Technology Call (RITC) 2026

The **European Partnership for Personalised Medicine, EP PerMed** (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), is a platform for joint programming of national and European regional research and innovation supporting activities putting into action "The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)"<sup>1</sup>, **SRIA for PM (2023)**, through dedicated research, development and innovation funding.

EP PerMed funding organisations, listed below, have agreed to launch a Research, Innovation and Technology Call (RITC) 2026, co-funded by the EU, to fund multinational, innovative research projects in personalised medicine, which should bring together teams from clinical/public health sector and enterprises as well as academic and non-for-profit teams. The RITC2026 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat (JCS), hosted by the French National Research Agency (ANR), France.

The call will be implemented in two stages, i.e. a pre- and a full-proposal phase. The available budget for this call is **13 Mio. € (approx.)**.

An **information day introducing the RITC2026** to the research community will be organised on 28 October 2025. More details (including the registration) will follow soon.

### Expected timeline of the call

<b>July/August 2025</b>	Pre-announcement of the call
<b>Beginning of October 2025</b>	Publication of the call
<b>28 October 2025</b>	RITC2026 Information Day
<b>12 January 2026 (14:00, CET)</b>	Deadline for pre-proposal submission
<b>Around mid-March 2026</b>	Communication of the results of the pre-proposal assessment and invitation to the full-proposal stage
<b>27 April 2026 (14:00, CEST)</b>	Deadline for full-proposal submission
<b>End of June 2026</b>	Rebuttal stage
<b>Expected for September 2026</b>	Communication of the funding decisions to the applicants
<b>End of 2026, beginning of 2027</b>	Expected project start (according to regional/national funding regulations)

<sup>1</sup> <https://www.eppermed.eu/action-areas/sria/>

## Aims of the Call

This call aims to bring together enterprises with clinical actors, including healthcare providers, patients, and researchers, to test innovative solutions in controlled real-world settings to address clear needs in managing multimorbidity.

EP PerMed will fund innovation projects in human health that focus on multimodal data usage for PM approaches providing more efficient and personalised management of multimorbid patients, having at least two chronic diseases that require management.

Projects will address one or more of the following aspects:

- Detection or characterisation of co-morbidities in chronically ill patients;
- Diagnosis, follow-up or monitoring of disease progression, including remissions and relapses;
- Promoting a shift from in-patient to out-patient care through remote monitoring or reporting using wearables or other technical solutions;
- Decision support for disease intervention strategies (e.g., medication type and dosage);
- Tracking and managing multiple treatments (including drug combinations) to improve effectiveness or reduce adverse effects and potential harmful drug interactions;
- Adherence to long-term treatment regimens.

Funded projects are required to test and further develop mature solutions in controlled real-world environments. They should also adopt a holistic system approach by integrating six enabling elements (knowledge integration; technologies, products, methods and processes; infrastructures; business and value models; policies and regulations; organisation; behaviour and values). Furthermore, proposals must clearly describe a robust strategy for the collection, processing, and usage of multimodal health data.

The transnational consortia have mandatorily to include a clinical partner as well as at least one SME (small and medium sized enterprise) or industry partner.

While clinical studies can be funded in this call, larger clinical trials are out of scope.

## General (Eligibility) Conditions for Application

Joint research proposals may be submitted by applicants belonging to the following categories (subject to regional/national funding regulations):

- A. Enterprise (for-profit) of all sizes**, e.g. SME<sup>2</sup> (small and medium-sized enterprises) and industry.
- B. Clinical partner**, public or private health sector represented by research teams or clinicians (e.g. medical doctors, nurses or pharmacists) working in hospitals/public health or other healthcare settings and health organisations).

---

<sup>2</sup> [https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition\\_en](https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en)

- C. Academia**, research teams working in universities, other higher education institutions or public or private research institutes.
- D. Private non-profit partners**, e.g. foundations, associations or non-governmental organisations.

Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EP PerMed funding organisation/s respective of the region/country from which applicants applies. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/ national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below "*Contact details of participating members*").

More information about the eligibility criteria and rules regarding consortium composition will be available soon.

## Partnering Tool

A new partnering tool developed and supported by the EP PerMed will be available for the call.

## Participating Countries and European National Regions

The following countries (16) are participating in the preparation of the call: Belgium, Czech Republic, Finland, France, Ireland\*, Israel, Italy, Latvia, Lithuania, , Portugal, Romania\*, Slovak Republic, South Africa\*, Spain, Sweden and Turkiye\* (contact list is provided below).

Besides national funders, the following regions are participating (5): Flanders (Belgium), Wallonia (Belgium)\*, Centro Region (Portugal), Andalusia (Spain) and Navarre (Spain).

*\*Final decision on participation is still pending*

### **Please note:**

The information provided in this pre-announcement is indicative and may be subject to changes and is not legally binding to funding organisations. Additional funding organisations might join the call before the official publication or leave the funders consortium.

Interested applicants are encouraged to initiate scientific contacts with potential project consortium partners for applications.

The final call information is expected to be published on the EP PerMed website in October 2025.

**For more information:** <https://www.eppermed.eu/RITC2026>

## List of Regional/National Contacts

<b>Name of participating organisation</b>	<b>Country/Region</b>	<b>Regional/National contact</b>
<b>Vlaams Gewest - VLAIO Flanders Innovation &amp; Entrepreneurship (FIO-VLAIO)</b>	Belgium (Flanders)	<i>More information to come</i>
<b>Service Public de Wallonie (SPW EER)*</b>	Belgium (Wallonie)	
<b>The Ministry of Health of the Czech Republic / Czech Health Research Council, (MZCR/AZVCR)</b>	Czech Republic	
<b>Business Finland, (BFRK)</b>	Finland	
<b>Agence Nationale de la Recherche, (ANR)</b>	France	
<b>Health Research Board (HRB)*</b>	Ireland	
<b>Chief Scientist Office, Ministry of Health, (CSO-MOH)</b>	Israel	
<b>Italian Ministry of Health, (IT-MoH)</b>	Italy	
<b>Latvian Council of Science, (LZP)</b>	Latvia	
<b>Research Council of Lithuania, (LMT)</b>	Lithuania	
<b>Comissão de Coordenação e Desenvolvimento Regional do Centro, (CCDRC)</b>	Portugal (Centro Region)	
<b>Executive Unit for Research, Development and Innovation Higher Education Funding (UEFISCDI)*</b>	Romania	
<b>Slovak Center of Science and Technical Information (CVTI SR)</b>	Slovak Republic	

<b>Name of participating organisation</b>	<b>Country/Region</b>	<b>Regional/National contact</b>
<b>South African Medical Research Council (SAMRC)*</b>	South Africa	
<b>Consejería de Salud y Consumo de la Junta de Andalucía, (CSCJA)</b>	Spain (Andalusia)	
<b>Government of Navarre, (CFN)</b>	Spain (Navarre)	
<b>Sweden´s Innovation Agency, (VINNOVA)</b>	Sweden	
<b>The Scientific and Technological Research Council of Turkey, (TUBITAK)*</b>	Turkiye	

\* Final decision for participation is still pending.